Simcere Pharmaceutical Group Limited
2096
Rank in Stocks
#4480
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-AĆ). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Share Price
$1.32
Market Cap
$3.40B
Change (1 day)
-4.51%
Change (1 year)
-19.88%
Country
CN
Trade Simcere Pharmaceutical Group Limited (2096)
Category
Healthcare
Revenue for Simcere Pharmaceutical Group Limited (2096)
Revenue in Oct 2026 TTM: 0
According to Simcere Pharmaceutical Group Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Simcere Pharmaceutical Group Limited from 2012 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2025 | $1.11B | 21.56% |
| 2024 | $909.04M | -2.62% |
| 2023 | $933.49M | 1.90% |
| 2022 | $916.09M | 16.46% |
| 2021 | $786.63M | 13.97% |
| 2020 | $690.18M | -4.58% |
| 2019 | $723.31M | 10.22% |
| 2018 | $656.27M | 10.39% |
| 2017 | $594.50M | 77.98% |
| 2012 | $334.03M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
